Introduction
Garenoxacin (BMS-284756, T-3811ME) is a novel des-F(6)-quinolone available for oral and parenteral administration. It is currently in Phase III of its development, and has been shown to have broad-spectrum activity against Gram-positive and -negative organisms, 1 as well as 'atypical' organisms. 2 The aim of this study was to measure concentrations of garenoxacin, using a previously validated microbiological assay, 3 in plasma and compartments of the respiratory tree following a single 600 mg oral dose. For therapeutic efficacy, it is important that adequate concentrations of antibiotic are found at potential sites of respiratory infection, 4 and quinolones have been shown previously to penetrate lung tissues more efficiently than β-lactam antibiotics. 5 
Materials and methods

Subjects
Twenty-four healthy subjects, 14 men (mean age 22.4 years, mean weight 81.8 kg) and 10 women (mean age 29.5 years, mean weight 57.5 kg), were enrolled into the study at Hammersmith Medicines Research at the Central Middlesex Hospital in London, UK. Subjects were dosed with 600 mg oral garenoxacin, and the plasma and lung tissue samples were collected at one of four time intervals: interval 1, 2.5-3.5 h; interval 2, 4.5-5.5 h; interval 3, 10.5-11.5 h; and interval 4, 23.5-24.5 h. The Hospital Ethics Committee approved the study and all subjects gave written informed consent. All subjects were screened within 14 days prior to bronchoscopy; 
Sample collection
Bronchoscopy samples were collected as described previously. 6 Briefly, at bronchoscopy bronchial mucosa (BM) and broncho-alveolar lavage (BAL) were taken using standard procedures. 7 In the case of BAL, 200 mL of pre-warmed 0.9% saline was divided into four 50 mL aliquots. The aspirate from the first aliquot was discarded to avoid contamination of the sample with proximal airway fluids and cells; the remaining aspirates were pooled for analysis.
Microbiological assay
Concentrations of garenoxacin were measured using methods based on those described previously. 8 Assay plates (Mast Diagnostics, Bootle, UK) containing Iso-Sensitest agar (Oxoid, Basingstoke, UK) were flooded with an Escherichia coli (4004; Bayer, Wuppertal, AG, Germany) suspension adjusted to an optical density of 0.004 at 630 nm. Antibiotic calibrators were prepared in pooled human serum and pH 7 buffer (range 0.06-1 mg/L) and 9% saline (range 0.12-2 mg/L). Internal control samples (0.8 and 0.08 mg/L prepared in human serum and pH 7 buffer; 1.5 and 0.2 mg/L prepared in 9% sodium chloride) and quality assurance samples (range 0.07-0.9 mg/L for human serum and pH 7 buffer; range 0.15-1.8 mg/L for 9% sodium chloride) were included on every assay plate. Five millimetre holes were punched in the agar, and tests, calibrators, control and quality assurance samples were applied in triplicate to the plate. After overnight incubation at 30°C, zones were measured using an image analyser pre-programmed with Bennet's calculation 9 (Imaging Associates, Thame, UK).
Calculation of garenoxacin in epithelial lining fluid (ELF), alveolar macrophages (AM) and BM
Concentrations of antibiotic were calculated using the following formulae:
BM.
where AC = assayed concentration (mg/L), VB = volume of buffer added to homogenize the sample (µL) and WS = weight of tissue (mg).
ELF. The concentration of urea in BAL was determined using a modified Sigma Diagnostic Kit (UV-66, Sigma Chemicals, Poole, UK).
where ACL = assayed concentration (mg/L), UL = urea concentration in lavage (mmol/L) and BL = blood urea concentration (mmol/L).
AM. Antibiotic concentration in AMs was determined using a mean cell volume of an alveolar macrophage of 2.48 µL/ 10 6 cells.
Results
The lower limit of quantification of the microbiological assay was 0.03 mg/L. Between-assay coefficients of variation (mean for the two concentrations tested) for internal controls prepared in human serum, pH 7 buffer, and 9% sodium chloride, were 6.4, 6.3 and 6%, respectively. All of the quality assurance samples prepared in human serum and 9% saline were within ±15% of the assigned concentration. In the case of pH 7 buffer, ≥96.2% were within ±15% of the assigned concentration, and 100% were within ±20%. Control urea samples included with every batch of urea estimations were within ±10% of the assigned concentration. For two subjects, urea concentrations in the BAL were below the limits of quantification. For the remaining 22 subjects, the mean urea concentration in BAL was 0. Table 1 . The mean site to plasma ratios are shown in Figure 1 .
No drug-related adverse events were observed. However, a total of 14 adverse events (mostly mild in intensity) were noted to have occurred during or immediately after the BAL procedure; these were considered unlikely/unrelated to the study drug, with the BAL procedure being cited in all cases as the most likely cause.
Discussion
This study has demonstrated that concentrations of garenoxacin, at all potential sites of respiratory infection for a 24 h period, exceeded a tentative MIC breakpoint of 0.5 mg/L (MIC 90s for Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae, including isolates with reduced susceptibility to penicillin of 0.03, 0.015 and 0.06 mg/L, respectively) that has been suggested for this antibiotic. 10 In the case of isolates of S. pneumoniae with reduced susceptibility to quinolones (ciprofloxacin MICs ≥ 4 mg/L and garenoxacin MICs 0.06 and 1 mg/L), 1,2 these data confirm that mean concentrations at each of the sites exceed the MICs of garenoxacin. Mean garenoxacin concentrations in BM at the last sampling interval (23.5-24.5 h post-dose) exceeded the garenoxacin MIC 90 s for S. pneumoniae, H. influenzae and M. catarrhalis, by ∼29-, 58-and 115-fold, respectively. These fold increases are greater than corresponding fold increases noted for moxifloxacin (4-, 17-and 17-fold, respectively). 11 Like other quinolones, we have shown a high penetration into AMs that would suggest that this drug should exhibit efficacy against Mycoplasma, Legionella and Chlamydia. 12 
